Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HPN, and Holz FG. Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study. Am J Ophthalmol 2011; 151(5): 876-886.

In the May 2011 issue of the American Journal of Ophthalmology, an error is reported in the above article. Towards the end of the last paragraph of the article, the text reads, “While the unchanged distance visual acuity at the 12 month follow-up would have suggested a stable disease course, microperimetry revealed a progressive paracentral loss of retinal light sensitivity (study eye: −2.3dB; SD 2.4; p= 0.01; fellow eye: 1.3dB; SD 1.6; p = 0.03; assessed were 9 testing points covering an area of 3×3 degrees temporal to the foveal center) due to continuing photoreceptor degeneration.” ³⁰

The value for “fellow eye” in the above paragraph incorrectly appears as “1.3dB.” The correct value is “−1.3db.”

The authors regret this error.